Liposomal amphotericin B (AmBisome®) and sodium stibogluconate + Liposomal amphotericin B + miltefosine + Miltefosine
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Visceral Leishmaniasis
Conditions
Primary Visceral Leishmaniasis
Trial Timeline
Mar 1, 2010 → Jun 1, 2011
NCT ID
NCT01067443About Liposomal amphotericin B (AmBisome®) and sodium stibogluconate + Liposomal amphotericin B + miltefosine + Miltefosine
Liposomal amphotericin B (AmBisome®) and sodium stibogluconate + Liposomal amphotericin B + miltefosine + Miltefosine is a phase 2 stage product being developed by Gilead Sciences for Primary Visceral Leishmaniasis. The current trial status is completed. This product is registered under clinical trial identifier NCT01067443. Target conditions include Primary Visceral Leishmaniasis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01067443 | Phase 2 | Completed |
Competing Products
20 competing products in Primary Visceral Leishmaniasis